Ipsen Valuation

Is 0MH6 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0MH6 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0MH6 (€110.46) is trading below our estimate of fair value (€284.86)

Significantly Below Fair Value: 0MH6 is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0MH6?

Other financial metrics that can be useful for relative valuation.

0MH6 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.7x
Enterprise Value/EBITDA8.1x
PEG Ratio2x

Price to Earnings Ratio vs Peers

How does 0MH6's PE Ratio compare to its peers?

The above table shows the PE ratio for 0MH6 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average25.9x
HIK Hikma Pharmaceuticals
19.7x13.1%UK£4.2b
GSK GSK
15.1x14.3%UK£61.0b
AZN AstraZeneca
38.2x16.5%UK£185.2b
ANCR Animalcare Group
30.4x15.8%UK£140.7m
0MH6 Ipsen
13.9x7.0%€9.2b

Price-To-Earnings vs Peers: 0MH6 is good value based on its Price-To-Earnings Ratio (13.9x) compared to the peer average (25.9x).


Price to Earnings Ratio vs Industry

How does 0MH6's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a16.3%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a16.3%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: 0MH6 is good value based on its Price-To-Earnings Ratio (13.9x) compared to the European Pharmaceuticals industry average (23x).


Price to Earnings Ratio vs Fair Ratio

What is 0MH6's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0MH6 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio13.9x
Fair PE Ratio27.2x

Price-To-Earnings vs Fair Ratio: 0MH6 is good value based on its Price-To-Earnings Ratio (13.9x) compared to the estimated Fair Price-To-Earnings Ratio (27.2x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0MH6 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€110.46
€127.19
+15.1%
12.6%€165.00€110.00n/a16
Sep ’25€109.20
€126.50
+15.8%
12.4%€165.00€110.00n/a16
Aug ’25€103.04
€126.50
+22.8%
12.4%€165.00€110.00n/a16
Jul ’25€114.76
€127.28
+10.9%
12.1%€165.00€110.00n/a16
Jun ’25€120.22
€126.40
+5.1%
11.5%€161.00€110.00n/a16
May ’25€112.25
€125.29
+11.6%
11.9%€161.00€110.00n/a15
Apr ’25€110.28
€124.83
+13.2%
11.7%€160.00€110.00n/a15
Mar ’25€101.39
€124.83
+23.1%
11.7%€160.00€110.00n/a15
Feb ’25€105.90
€125.49
+18.5%
12.6%€165.00€110.00n/a15
Jan ’25€108.01
€127.31
+17.9%
13.3%€164.00€110.00n/a14
Dec ’24€102.61
€127.95
+24.7%
13.0%€164.00€110.00n/a14
Nov ’24€112.91
€127.82
+13.2%
13.2%€165.00€106.00n/a15
Oct ’24€124.26
€127.93
+3.0%
13.0%€163.00€106.00€110.3515
Sep ’24€118.52
€125.00
+5.5%
12.4%€163.00€106.00€109.2016
Aug ’24€115.99
€120.06
+3.5%
14.3%€159.00€100.00€103.0416
Jul ’24€110.23
€118.00
+7.0%
14.8%€159.00€100.00€114.7616
Jun ’24€110.68
€117.06
+5.8%
13.9%€159.00€100.00€120.2216
May ’24€109.72
€116.19
+5.9%
12.8%€159.00€100.00€112.2516
Apr ’24€102.29
€114.25
+11.7%
13.0%€159.00€98.00€110.2817
Mar ’24€106.70
€113.48
+6.4%
10.6%€142.00€98.00€101.3917
Feb ’24€96.95
€111.42
+14.9%
12.6%€142.00€86.00€105.9017
Jan ’24€101.00
€110.44
+9.4%
12.1%€142.00€86.00€108.0118
Dec ’23€107.20
€108.88
+1.6%
12.2%€142.00€86.00€102.6116
Nov ’23€103.71
€107.06
+3.2%
13.0%€142.00€86.00€112.9116
Oct ’23€94.68
€106.56
+12.6%
12.8%€139.00€84.00€124.2616

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies